The response of peripheral blood lymphocytes to stimulation by mitogens such as phytohaemagglutinin (PHA) is commonly depressed in both rheumatoid arthritis and iron deficiency, and as many rheumatoid patients are anaemic with evidence of abnormal iron metabolism it is possible that the same mechanism underlies the observed suppression in both conditions. In the present study the mitogenic response to PHA of lymphocytes from three rheumatoid patients, who were also iron deficient, and two healthy controls has been shown to be significantly less in iron deficient than iron containing media (p<0001). In addition, iron deficient sera from these patients reduced the PHA induced proliferation of lymphocytes from a normal subject (p<0-01), an effect which was prevented by prior addition of iron to these serum samples. In iron containing media lymphocytes from five patients and two controls showed no difference in their response to PHA for both the minimum mitogen concentration which enhanced transformation and the peak [3H]thymidine uptake; but patients' lymphocytes showed significantly less response to PHA concentrations of 5 and 10 mg/l (p<002), resulting in a reduction in the area under the dose response curves up to 20 mg/l (p<0-05). These findings show both that iron deficient sera can impair PHA induced lymphocyte transformation and that lymphocytes from iron deficient rheumatoid patients have impaired responsiveness to PHA. Iron is known to be required intracellularly for the enzyme ribonucleotide reductase, which is important for DNA synthesis, and reduced activity of this enzyme could explain these observed effects.
SUMMARY
The response of peripheral blood lymphocytes to stimulation by mitogens such as phytohaemagglutinin (PHA) is commonly depressed in both rheumatoid arthritis and iron deficiency, and as many rheumatoid patients are anaemic with evidence of abnormal iron metabolism it is possible that the same mechanism underlies the observed suppression in both conditions. In the present study the mitogenic response to PHA of lymphocytes from three rheumatoid patients, who were also iron deficient, and two healthy controls has been shown to be significantly less in iron deficient than iron containing media (p<0001). In addition, iron deficient sera from these patients reduced the PHA induced proliferation of lymphocytes from a normal subject (p<0-01), an effect which was prevented by prior addition of iron to these serum samples. In iron containing media lymphocytes from five patients and two controls showed no difference in their response to PHA for both the minimum mitogen concentration which enhanced transformation and the peak [3H]thymidine uptake; but patients' lymphocytes showed significantly less response to PHA concentrations of 5 and 10 mg/l (p<002), resulting in a reduction in the area under the dose response curves up to 20 mg/l (p<0-05). These findings show both that iron deficient sera can impair PHA induced lymphocyte transformation and that lymphocytes from iron deficient rheumatoid patients have impaired responsiveness to PHA. Iron is known to be required intracellularly for the enzyme ribonucleotide reductase, which is important for DNA synthesis, and reduced activity of this enzyme could explain these observed effects.
In patients with rheumatoid arthritis the response of peripheral blood lymphocytes to the mitogens phytohaemagglutinin (PHA) and concanavalin A (con A) is fairly consistently depressed. - Results for lymphocyte transformation are expressed as either cpm/well, or mean transformation index (cpm/well after stimulation with PHA divided by the cpm/well without mitogen) and compared using Wilcoxon's matched pairs signed ranks test for non-parametric data. In addition, the results were converted to log,( cpm and compared using Student's t test for paired and unpaired data as appropriate. Two tailed tests were used throughout.
Results
Lymphocyte viability as assessed by trypan blue exclusion was always greater than 98% before culture and greater than 95% in both iron containing and iron deficient media at the end of the culture period. The iron content of the citrate treated sera as determined by a standard laboratory semiautomated process (and based on the method of Young and Hicks16) was found to be less than 2 itmol/l, while the Chelex treated culture media contained less than 2 tg/l as determined by flameless atomic absorption spectrophotometry.
When all three iron deficient incubation media are considered together PHA induced mitogenesis was markedly reduced for lymphocytes from both patients (p<0.0001) and controls (p<0-001; Table 2 ).
Similar reductions were seen for each medium individually in the patients (p<0-05), and for fetal calf and pooled normal serum in the controls (p<0-05). These changes remained significant when the mean transformation indices were calculated ( Table 2 ). The reduction of spontaneous, unstimulated proliferation of lymphocytes by the iron deficient conditions was greater than that of the PHA transformed cells, which resulted in mean transformation indices that were actually higher in iron deficient than in iron containing media. Addition of pooled normal serum resulted in the greatest DNA synthesis for most patients and controls in both iron containing (p<005) and iron deficient media, but there was no difference between media containing homologous sera or fetal calf sera. Native iron deficient serum from three patients with rheumatoid arthritis led to a significant reduction in the uptake of [3H]thymidine by lymphocytes from a normal subject (p<OO1), which was reversed by prior addition of iron to the serum samples. The mean transformation indices were, however, greater in the iron deficient than in the iron containing media (p<005; Table 3 ). In iron containing RPMI 1640 medium with 10% FCS and antibiotics lymphocytes from all subjects underwent transformation when treated with PHA ( Fig. 1) , with no significant differences between cells from patients and controls when the response to mitogen was characterised by the minimum mitogen concentration eliciting a response (2-5 mg/i) or by the peak [3H]thymidine uptake (Table 4) . With PHA concentrations of 5 and 10 mg/l, however, there was significantly less response with lymphocytes from the iron deficient rheumatoid patients than from controls ip<0-02), resulting in a reduction in the cumulative [ H]thymidine uptake up to PHA concentrations of 20 mg/l (p<005), though by a concentration of 50 mg/i this was no longer seen. There was no correlation between responsiveness to PHA and degree of iron deficiency in these patients.
Discussion
Iron deficiency has been shown to inhibit markedly the response to PHA of lymphocytes from both rheumatoid patients and controls (p<0-001) without affecting cell viability. Similarly, iron deficient sera from three patients inhibited the transformation of lymphocytes from a normal subject (p<0-01), and this effect was prevented by prior addition of iron to these serum samples.
Similar results were foynd4in in vitro studies,7 in which the degree of priiferation to con A of mouse lymphocytes from iron deficient and normal animals in serum free medium containing apotransferrin was significantly lower than in media containing 20% iron saturated transferrin or 10% fetal calf serum. Irrespective of the iron status of the animal, proliferation of cells was lower in media supplemented with serum from iron deficient mice than when serum from normal or iron replete mice was used. The addition of iron to the iron deficient serum also significantly improved its ability to promote proliferation, whereas in vivo repletion of iron deficient mice resulted in restoration of normal lymphocyte responsiveness to con A. Human studies have also shown a decreased in vitro proliferation of lymphocytes from iron deficient patients using media supplemented with their own sera. 17 18 In the present study lymphocytes from iron deficient rheumatoid patients, when incubated in iron containing media, respond to stimulation with PHA in a similar manner to cells from normal subjects, particularly with regard to the minimum mitogen concentration eliciting a response and the peak [3H]thymidine uptake. With lower PHA concentrations, however, the proliferation of lymphocytes from patients was reduced, resulting in a significantly lower cumulative [3H]thymidine incorporation (p<O0O5). This would be consistent with an intrinsic defect in the patient's cells which is partially inhibiting the proliferative response to PHA. A reduction in the number or affinity of lectin binding sites, reduced interleukin 2 production, or reduced binding to interleukin 2 receptors is possible, though it is unclear at present whether such changes occur consistently in rheumatoid arthritis.'9 The role of transferrin and its receptor in lymphocyte proliferation is well known,20 and although activation antigens were not examined in the present study, others have shown an increase in the number of rheumatoid inflammatory T cells that express transferrin receptors.2' Failure of expression of this receptor is, therefore, unlikely to account for the diminished response to PHA seen in the present study. At a cellular level iron is an essential cofactor for the enzyme ribonucleotide reductase, which is required for the production of deoxyribonucleoside diphosphates in the synthesis of DNA,22 23 and indeed clinical studies have shown a reduction in the metabolites of deoxyribonucleoside diphosphates in iron deficient patients. 24 In other studies into PHA induced lymphocyte responsiveness in rheumatoid arthritis it has been stressed that inhibition of proliferation is best shown by examining dose response curves, calculated from the cumulative [3H]thymidine uptake at all concentrations of mitogen, rather than the response to specific concentrations,2 and that impaired responsiveness is associated with disease activity3 and particularly with erosive arthropathy.2 Unfortunately, in these studies there is no mention of the iron status of the patients, though it is known that iron deficiency is common in rheumatoid vatients and that this correlates with disease activity. Awareness of the role of iron deficiency in PHA induced lymphocyte transformation is particularly relevant in studies where autologous serum is added to the media,' as lack of iron in this serum will exacerbate the effect of any intrinsic cellular defect.
In the report by Highton and colleagues lymphocyte responsiveness to various mitogens in rheumatoid patients returned to normal after [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] weeks' treatment with sodium aurothiomalate, and it was suggested that this was due to lessening of rheumatoid disease activity.5 These workers found, as in our study, that serum samples from some of their patients were capable of suppressing the function of normal lymphocytes, and that this effect was less apparent after treatment. This suppressive effect did not correlate with concentrations of C reactive protein or rheumatoid factor, but there was an inverse relation between the responsiveness of normal lymphocytes with patient sera and the level of Clq binding activity. Although it is possible that immune complexes in serum may be one factor leading to suppression of lymphocyte function in rheumatoid arthritis, there is no mention of the iron status of these patients before and after their gold treatment, which may provide an alternative explanation for the observed effects.
Iron deficiency may not be the only factor in the impaired proliferative response to PHA in patients with rheumatoid arthritis, but the results of the present study do emphasise the need to include the iron status of patients in the interpretation of results from studies of this type.
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